The aim of this study was to establish whether the factor V Leiden mutation and the prothrombin 20210 G:A mutation were risk factors for retinal vein occlusion.
Methods
Blood samples were obtained from 40 patients with retinal vein occlusion and from 50 healthy normal volunteers as controls. Polymerase chain reaction assays were done to detect factor V Leiden and prothrombin 20210 G:A mutations, and the two groups were compared.
Results
Two (5%) of 40 patients with retinal vein occlusion and three (6%) of 50 controls were heterozygous for factor V Leiden (p=0.84). None of the individuals in either group had the prothrombin 20210 G:A mutation.
Conclusions
There was no significant association between retinal vein occlusion and the factor V Leiden mutation.
ClarksonJ.G.. Central retinal vein occlusion. In: SchachatA.P., MurphyR.P., PatzA., eds. Medical Retina. Vol 2 of Ryan SJ, ed. Retina. St. Louis: C.V. Mosby, 1994; 421–6.
2.
FinkelsteinD.. Retinal branch vein occlusion. In: SchachatA.P., MurphyR.P., PatzA., eds. Medical Retina. Vol 2 of Ryan SJ, ed. Retina. St. Louis: C.V. Mosby, 1994; 427–32.
3.
RalthE.Z., FrankR.N., ShinD.H., KimC.. Risk factors for retinal vein thrombosis: A case-control study.Ophthalmology1992; 3: 109–13.
4.
The Eye Disease Case-Control Study Group.Risk factors for branch retinal vein occlusion.Am J Ophthalmol1993; 116: 286–96.
5.
Central Retinal Vein Occlusion Study Group.Baseline and early natural history report: the central retinal vein occlusion study.Arch Ophthalmol1993; 111: 1087–95.
6.
FongA.C., SchatzH.. Central retinal vein occlusion in young adults.Surv Ophthalmol1993; 37: 393–417.
7.
DahlbackB., CarlssonM., SvenssonP.J.. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C.Proc Natl Acad Sci USA1993; 90: 1004–8.
8.
SvenssonP.J., DahlbackB.. Resistance to activated protein C as a basis for venous thrombosis.N Engl J Med1994; 330: 517–22.
9.
GrevenC.M., WallA.B.. Peripheral retinal neovascularization and retinal vascular occlusion associated with activated protein C resistance.Am J Ophthalmol1997; 124: 687–9.
10.
LarssonJ., OlafsdottirE., BauerB.. Activated protein C resistance in young adults with central retinal vein occlusion.Br J Ophthalmol1996; 80: 200–2.
11.
WilliamsonT.H., RumleyA., LoweG.D.O.. Blood viscosity, coagulation, and activated protein C resistance in central retinal vein occlusion: a population controlled study.Br J Ophthalmol1996; 80: 203–8.
12.
GrahamS.L., GoldbergI., MurrayB., BeaumontP., ChongB.H.. Activated protein C resistance: low incidence in glaucomatous disc hemorrhage and central retinal vein occlusion.Aust NZJ Ophthalmol1996; 24: 199–205.
13.
GottliebJ.L., BliceJ.P., MestichelliB., KonkleB.A., BensonW.E.. Activated protein C resistance, factor V Leiden, and central retinal occlusion in young adults.Arch Ophthalmol1998; 116: 577–9.
14.
BertinaR.M., KoelemanP.C., KosterT.Mutation in blood coagulation factor V associated with resistance to activated protein C.Nature1994; 369: 64–7.
15.
DahlbackB., HildebrandB.. Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor V.Proc Natl Acad Sci USA1994; 81: 1396–1400.
16.
ReesD.C., CoxM., CleggJ.B.. World distribution of factor V Leiden.Lancet1995; 346: 1133–4.
17.
LinnaT., YlikorkalaA., KontulaK., PuskaP., TervoT.. Prevalence of Factor V Leiden in young adults with retinal vein occlusion.Thromb Haemost1997; 77: 214–6.
18.
GlueckC.J., BellH., VadlamaniL.Heritable thrombophilia and hypofibrinolysis.Arch Ophthalmol1999; 117: 43–9.
19.
HodgkinsP.R., PerriD.J., SawcerS.J.Factor V and antithrombin gene mutations in patients with idiopathic central retinal vein occlusion.Eye1995; 9: 760–2.
20.
CiardellaA.P., YannuzziL.A., FreundK.B.Factor V Leiden, activated protein C resistance, and retinal vein occlusion.Retina1998; 18: 308–15.
21.
PoortS.R., RosendaalF.R., ReitsmaP.H., BertinaR.M.. A common genetic variation in the 3′-untranslated region of prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis.Blood1996; 88: 3698–703.
22.
IncorvaiaC., LambertiG., ParmeggianiF.Idiopathic central retinal vein occlusion in a thrombophilic patient with the heterozygous 20210 G/A prothrombin genotype.Am J Ophthalmol1999; 128: 247–8.
23.
KlingF., MacarezR., RobinetA., KouassiF.X., ColinJ.. Mixed retinal thrombosis in a patient carrying prothrombin gene mutation in a homozygote state.J Fr Ophtalmol1999; 22: 979–81.
24.
LarssonJ., HillarpA.. The prothrombin gene G20210A mutation and platelet glycoprotein IIIa polymorphism PIA2 in patients with central retinal vein occlusion.Thromb Res1999; 15: 323–7.
25.
ChanL.C., BourkeC., LamC.K.Lack of activated protein C resistance in healthy Hong Kong Chinese blood donors correlation with absence of Arg506-Gln mutation of factor V.Thromb Haemost1996; 75: 522–3.
26.
HolmJ., ZollerB., BerntorpE., ErhardtL., DahlbackB.. Prevalence of factor V gene mutation among myocardial infarction patients and healthy controls is higher in Sweden than in other countries.J Intern Med1996; 239: 221–6.
27.
GuvenD., SaymalpN., KalayclD., DundarS., HaslripiH.. Risk factors in central retinal vein occlusion and activated protein C resistance.Eur J Ophthalmol1999; 9: 43–9.
28.
AkarN., AkarE., DalginG., SözüözA., ÖmürlüK., CinŞ. Frequency of Factor V (1691 G→A) mutation in the Turkish population.Thromb Haemost1997; 78: 1527–8.
